By Manish Kumar
In a bid to provide the economical relief to the cancer patients, the Cadila Pharmaceuticals has introduced the first novel product for cancer management The company has claims that the medicine named Mycidac-C will play a crucial role in the treatment of lung cancer.
Mycidac-C is the name of medicine, which has been launched by Cadila. According to company sources, Mycidac-C is an innovative research product for patients suffering from a cancer sub-type - non-small cell lung cancer. It has been said that the Drug Controller General of India has approved the drug for launch in India.
The price of the medicine will be at Rs 4,000 for 10 injections. The total cost of therapy to patients is estimated at Rs 40,000 - which the company claims is affordable as cancer treatment is generally exorbitant.
Cadila CMD Dr Rajiv Modi said, "It has taken us over a decade a huge investment and a dedicatd research and development team to develop this unique drug. We expect it to be available in the Indian market buy December 2013. Thereafter we will introduce it in other regions like SAARC countries and European markets over the next five years."
Needless to say, with a turnover of Rs 1200 crore, Cadila Pharmaceuticals is one of the largest privately held pharmaceutical companies in India. It sells products in over 50 countries around the world and caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, anti-diabetics and immunologicals